Final Results of the CATALYST Trial

Summary

• In a cohort with difficult-to-control type 2 diabetes and hypercortisolism, mifepristone resulted in clinically & statistically significant improvements in HbA1c and other comorbidities
  • Comparable reductions in HbA1c were observed in participants with and without adrenal imaging abnormalities
• Adverse events were consistent with mifepristone’s known safety profile
  • The most common adverse events were consistent with glucocorticoid withdrawal syndrome
  • Hypokalemia may be addressed by proactive initiation of a potassium-sparing diuretic, eg, spironolactone, in clinical practice (as opposed to a double-blind trial)
• In individuals with inadequately controlled type 2 diabetes and hypercortisolism, cortisol-directed medical therapy with mifepristone significantly reduced HbA1c

Download poster